Therapeutic efficacy of sequential therapy with OK-432, cyclophosphamide, IL2-cultured lymphocytes and in vivo IL2 against advanced murine plasmacytoma

Biotherapy. 1989;1(3):197-206. doi: 10.1007/BF02170888.

Abstract

BALB/c mice inoculated IP with a syngeneic plasmacytoma MOPC104E were treated with a combination of a streptococcal preparation, OK-432 (1 KE, 0.1 mg/mouse), low-dose of cyclophosphamide (CPA, 1 mg/kg) and adoptive transfer of tumor-bearer-spleen cells (2 x 10(7) cells) cultured with IL2 and sonicated tumor extract (adoptive immunotherapy; AIT). The consecutive protocol of OK-432 (day 8, 9 post inoculation) - CPA (day 10) - AIT (day 11) was the most effective. Rate of complete remission was highest when recombinant (r-) IL2 was injected to the mice after AIT. Moreover, another bacterial preparation, Nocardia rubra cell wall skeleton and another low-dose chemotherapy, Mitomycin C could be used successfully instead of OK-432 or CPA. Transfer test of intraperitoneal cells (tumor cells plus host cells) of mice on day 11 post inoculation (on the day of AIT) revealed that OK-432 augmented the susceptibility of peritoneal cells to cultured lymphocytes in inhibition of transplantability, and that CPA after OK-432 augmented the anti-tumor effect of tumor-bearer-spleen cells which act synergistically with cultured lymphocytes. This therapy schedule seems to be the best model to augment the effect of AIT with minimal side effect.

MeSH terms

  • Animals
  • Biological Products / therapeutic use*
  • Combined Modality Therapy
  • Cyclophosphamide / therapeutic use*
  • Immunization, Passive*
  • Interleukin-2 / therapeutic use*
  • Killer Cells, Lymphokine-Activated / immunology*
  • Killer Cells, Lymphokine-Activated / transplantation
  • Male
  • Mice
  • Mice, Inbred BALB C
  • Peritoneal Cavity / cytology
  • Picibanil / therapeutic use*
  • Plasmacytoma / immunology
  • Plasmacytoma / therapy*
  • Spleen / cytology

Substances

  • Biological Products
  • Interleukin-2
  • Picibanil
  • Cyclophosphamide